16 results about "Amyloid deposition" patented technology

It is provided an anti-Aβ34 antibody and its use for diagnosing Alzheimer's disease in a patient, comprising obtaining a sample from the patient, detecting the level of Aβ34 in the sample by contacting the sample with the anti-Aβ34 antibody and detecting binding between Aβ34 and the antibody, and diagnosing the patient with Alzheimer's disease when the presence of Aβ34 in the sample is detected, alone or in combination with detecting an amyloid deposition marker such as Aβ42 and determining the ratio of Aβ34 / Aβ42.

The present disclosure provides methods and compositions for treating progeria or neurodegenerative diseases, particularly neurodegenerative diseases associated with amyloid deposition and neuronal death, such as Alzheimer's disease. Accordingly, aspects of the present disclosure relate to methods for treating progeria in a subject in need thereof, comprising administering to the subject a TERT-activating therapeutic agent. Other aspects relate to methods for treating a neurodegenerative disease in a subject, comprising administering to the subject a TERT-activating therapeutic agent.

The present invention refers to dopaminergic drugs such as dopamine precursors and aromatic L-amino acid decarboxylase (AADC) inhibitors for use in a treatment to delay the progression of pathologies in which abnormal amyloid deposits spread to different brain regions, consisting of Spinocerebellar Ataxia Type 3 and Alzheimer's Disease, administered in levodopa-equivalent doses below 300 mg / day. The present invention further refers to pharmaceutical formulations comprising the said dopaminergic drugs. The present invention's compounds pharmaceutical formulations and uses may be advantageously employed in a treatment to prevent further accumulation of amyloid deposits in neurons, and minimize adverse effects associated with the prolonged use of dopamine precursors and / or their peripheral degradation.

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ, Abeta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide and an alpha-synuclein peptide.

The present invention provides a therapeutic method and pharmaceutical composition that are effective in removing existing amyloid deposits and improve the prognosis of ALA patients. The present invention relates to methods and pharmaceutical compositions for treating amyloid deposition diseases using chimeric (e.g., mouse-human) antibodies, including methods for treating amyloid deposition diseases, including cardiac involvement, by administering pharmaceutical compositions containing chimeric anti-amyloid fibril antibodies, which can improve myocardial function in patients diagnosed with light chain amyloidosis (ALA) including cardiac involvement, within three weeks of treatment.

Amyloid deposition is considered a viable biomarker for Alzheimer's disease which is expensive and less used modality to study amyloid spatial distribution in brain. The present disclosure addresses problems of conventional approaches which exhibit trade-off between performance and mode collapse. This disclosure provides a system and method for subject-specific amyloid position emission tomography (PET) translation using conditioned diffusion-based generative model. The present disclosure discloses an architecture for synthesizing subject-specific amyloid images with a diffusion model. First effectiveness of a relationship between Fluorodeoxyglucose (FDG) and amyloid PET images is identified. Further, a framework is provided to synthesize Amyloid PET by utilizing its connection to FDG PET of same subject and cross-subject trends in amyloid deposition by incorporating age, gender and disease status information in learning process. In the other words, a diffusion model inspired image translation is provided to synthesize Amyloid PET from FDG PET and cross-subject amyloid deposition patterns.

The present application relates to the technical field of Congo red derivative photocatalytic probe application, and particularly relates to a Congo red derivative photocatalytic probe, a preparation method and a use method thereof, comprising a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arene, the arene represents an aromatic heterocycle, and the aromatic heterocycle is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the present application can specifically label amyloid plaques in AD brain tissue slices, the binding affinity is significantly improved (Kd of Aβ 1‑40 The Congo red derivative photocatalytic probe can reveal the molecular heterogeneity of amyloid deposition and the key regulatory role of the mitochondrial autophagy-lysosome axis, provide a new tool for AD pathological mechanism research, support proteomic analysis and pathological mechanism analysis across brain regions (hippocampus / cortex), and protect the molecular structure and application in the research of neurodegenerative diseases.

The present disclosure provides compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA and, in some cases, the amount of APP protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom or sign of a neurodegenerative disease or disorder associated with APP. Such symptoms and markers include cognitive impairment (including memory and language skill decline), behavioral and psychological symptoms (such as emotional desert and lack of motivation), gait disorders, seizures, progressive dementia, and abnormal amyloid deposition.

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in treatment of amyloidosis. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating amyloidosis; and / or (ii) preparation of drugs for alleviating or reversing amyloid deposition. The invention also provides a method for reducing or reversing amyloid protein deposition by using the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof, or the pharmaceutical composition, and a method for preventing and / or treating amyloidosis. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose of continuously obtaining clinical deep remission treatment for patients with recurrent and refractory amyloidosis.

Provided herein are modified immunoglobulins comprising an amyloid reactive peptide joined to an antibody, as well as humanized antibodies that bind to human amyloid fibrils and antibody-peptide fusion proteins. Also provided herein are methods of treating amyloid-based diseases by administering a modified immunoglobulin, humanized antibody, or antibody-peptide fusion protein.

The invention relates to the technical field of application of Congo red derivative photocatalytic probes, in particular to a Congo red derivative photocatalytic probe as well as a preparation method and a use method thereof.The Congo red derivative photocatalytic probe comprises a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arenes, arene represents a heteroaromatic ring, and the heteroaromatic ring is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the invention can specifically mark amyloid plaques in AD brain tissue slices, the binding affinity is remarkably improved (Kd of Abeta1-40 is equal to 0.07 mu m), the molecular heterogeneity of amyloid deposition and the key regulation and control effect of mitochondrial autophagy-lysosomal axis are disclosed, a new tool is provided for AD pathological mechanism research, and the Congo red derivative photocatalytic probe has a wide application prospect. And cross-brain region (hippocampus / cortex) proteome analysis and pathological mechanism analysis are supported, and the molecular structure and application in neurodegenerative disease research are simulated to be protected.

The present application relates to the technical field of medicine, and more particularly to a polypeptide for inhibiting and / or eliminating beta-amyloid aggregation and application thereof. The present application first develops a functional active polypeptide ANI-1 which can act on diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease from multiple targets, so as to effectively prevent and treat the diseases. The polypeptide ANI-1 of the present application has the functions of eliminating A beta aggregation, delaying behavioral decline caused by beta-amyloid toxicity (anti-paralysis, promoting movement), inhibiting neurogenic inflammation related to beta-amyloid deposition and enhancing antioxidant defense, has better overall efficacy and neuroprotective potential, and can provide a new idea for developing a multi-target drug for diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease.

The invention belongs to the technical field of biomedicine, and discloses application of a CHOP gene in preparation of a medicine for treating Alzheimer's disease. According to the application disclosed by the invention, the fact that the beta amyloid deposition of AD can be effectively relieved by knocking out or knocking down the CHOP gene is determined for the first time, neuroinflammation in the brain can be reduced, and the spatial learning and memory ability disorder of AD transgenic mice can be effectively improved. A new target spot is provided for AD treatment, clinical transformation value is achieved, and a preparation with the CHOP gene knocked out or knocked down can be used for preparing the medicine for treating the Alzheimer's disease.

The invention discloses a computer-aided drug screening method, system and device based on an IAPP. The application proves that the SARS-CoV-2S / N protein is directly combined with the IAPP and promotes the pathological aggregation of the IAPP in a host body for the first time. It is found for the first time that new coronavirus infection induces activation of a pancreas islet microenvironment complement system, and pro-inflammatory factor release and endoplasmic reticulum stress synergistically aggravate beta cell function failure. Insulin secretion disorder caused by the fact that IAPP aggregation destroys the SNARE complex mediated insulin vesicle transportation process is found for the first time. The invention provides a brand new theory that the new coronavirus causes beta cell dysfunction by physically hijacking key functional proteins of a host, and discloses an age-dependent mechanism that the virus aggravates islet amyloid protein deposition in the elderly population. And a new theoretical basis and a treatment direction are provided for age-dependent management and viral metabolic disorder research of diabetes after epidemic.

The Alzheimer's disease diagnosis method using PET-CT images according to the present application can include: a process of generating a standard brain CT template in MNI (Montreal Neurological Institute) space from a CT image calculated by a PET-CT device; a process of calculating a whole cortex volume of interest (VOI) of a plurality of sub-regions in which the deposition of beta amyloid is above a certain value in a cortex ROI (cortex ROI) region based on the above standard brain CT template; and a process of calculating a percentage unit of each of the above plurality of sub-regions based on the amyloid deposition rate (Standardized uptake value ratio, SUVR) of each of the above plurality of sub-regions. 18 F-florbetaben (FBB) 18 F-florbetaben (FBB) 18 F-flutemetamol (FMM) 18 F-flutemetamol (FMM)

The invention relates to an inducing method and system of a systemic amyloid degeneration mouse model, and relates to the technical field of biomedical models, amyloid substances extracted from diseased tissues are injected into a standard strain laboratory mouse as an inducing medium, and the disease progress is controlled by regulating and controlling parameters such as injection dosage and frequency. The method successfully overcomes the defects that an existing model depends on scarce lines or genetic modification, the disease is unstable, and the deposition range is limited, typical amyloid protein deposition can be stably and repeatedly induced in multiple organs of the whole body, and the severity of the disease can be flexibly regulated and controlled according to research requirements. An ideal animal model tool which is low in cost, reliable in phenotype and convenient to popularize is provided for disease mechanism research and drug research and development.